Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Mehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, Naval Daver, Rashmi Kanagal-Shamanna, Sherry Pierce, Dawen Sui, Peng Wei, Farnoosh Khodakarami, Zhenya Tang, Mark Routbort, Carol A. Bivins, Elias J. Jabbour, L. Jeffrey Medeiros, Kapil Bhalla, Hagop M. Kantarjian, Farhad Ravandi, Joseph D. Khoury

Blood (2022) 140 (1): 58–72.

https://doi.org/10.1182/blood.2021013983

Published: 2022

Includes: Supplemental data

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

Nakhle S Saba, MD, Mondana Ghias, Rekha Manepalli, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Christopher Austin, MD, Kami Maddocks, John C. Byrd, MD, Suman Kambhampati, MD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 3819.

https://doi.org/10.1182/blood.V122.21.3819.3819

Published: 2013

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Nakhle Saba, MD, Min Shen, PhD, Mondana Ghias, Mohammed Farooqui, DO, Christopher Austin, MD, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 865.

https://doi.org/10.1182/blood.V120.21.865.865

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Warren Fiskus, Ph.D., Sunil Sharma, M.D., Sunil Abhyankar, MD, Joseph McGuirk, DO, David J. Bearss, PhD, Kapil Bhalla, MD

Blood (2012) 120 (21): 868.

https://doi.org/10.1182/blood.V120.21.868.868

Published: 2012

Journal Articles

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Aditya Mandawat, Warren Fiskus, Kathleen M. Buckley, Kelly Robbins, Rekha Rao, Ramesh Balusu, Jean-Marc Navenot, Zi-Xuan Wang, Celalettin Ustun, Daniel G. Chong, Peter Atadja, Nobutaka Fujii, Stephen C. Peiper, Kapil Bhalla

Blood (2010) 116 (24): 5306–5315.

https://doi.org/10.1182/blood-2010-05-284414

Published: 2010

Journal Articles

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

Yumin Hu, Weiqin Lu, Gang Chen, Hui Zhang, Yu Jia, Yue Wei, Hui Yang, Wan Zhang, Warren Fiskus, Kapil Bhalla, Michael Keating, Peng Huang, Guillermo Garcia-Manero

Blood (2010) 116 (15): 2732–2741.

https://doi.org/10.1182/blood-2009-11-256354

Published: 2010

Includes: Supplemental data

Journal Articles

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

Warren Fiskus, Rekha Rao, Pravina Fernandez, Bryan Herger, Yonghua Yang, Jianguang Chen, Ravindra Kolhe, Aditya Mandawat, Yongchao Wang, Rajeshree Joshi, Kelly Eaton, Pearl Lee, Peter Atadja, Stephen Peiper, Kapil Bhalla

Blood (2008) 112 (7): 2896–2905.

https://doi.org/10.1182/blood-2007-10-116319

Published: 2008

Journal Articles

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

Rekha Rao, Warren Fiskus, Yonghua Yang, Pearl Lee, Rajeshree Joshi, Pravina Fernandez, Aditya Mandawat, Peter Atadja, James E. Bradner, Kapil Bhalla

Blood (2008) 112 (5): 1886–1893.

https://doi.org/10.1182/blood-2008-03-143644

Published: 2008

Journal Articles

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

Aditya Mandawat, BS, Warren Fiskus, PhD, Andrea Jakubowski, Rekha Rao, PhD, Zixuan Wang, PhD, Pravina Fernandez, MS, Yongchao Wang, MS, Pearl Lee, BS, Anand Jillela, MD, Peter Atadja, PhD, Nobutaka Fujii, PhD, Stephen C. Peiper, MD, Kapil Bhalla, MD

Blood (2007) 110 (11): 537.

https://doi.org/10.1182/blood.V110.11.537.537

Published: 2007

Journal Articles

Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL.

Leandro Cerchietti, MD, Maria E. Figueroa, MD, David Meyers, PhD, Philip A. Cole, PhD, Kapil Bhalla, MD, Ari Melnick, MD

Blood (2007) 110 (11): 523.

https://doi.org/10.1182/blood.V110.11.523.523

Published: 2007

Journal Articles

Targeting Histone Deacetylases and Unfolded Protein Mediated Endoplasmic Reticulum (ER) Stress as a Strategy Against Human Mantle Cell Lymphoma.

Rekha Rao, PhD, Warren Fiskus, PhD, Rajeshree Joshi, BS, Jianguang Chen, PhD, Pravina Fernandez, MS, Yongchao Wang, MS, Pearl Lee, BS, Anand Jillella, MD, Jianguo Tao, MD, Peter Atadja, PhD, Eduardo Sotomayor, MD, Kapil Bhalla, MD

Blood (2007) 110 (11): 1378.

https://doi.org/10.1182/blood.V110.11.1378.1378

Published: 2007

Journal Articles

Molecular Characterization and Drug-Sensitivity of Pan Histone Deacetylase Inhibitor Resistant Human Acute Myeloid Leukemia Cells.

Warren Fiskus, PhD, Rekha Rao, PhD, Pravina Fernandez, MS, Bryan Herger, PhD, Yonghua Yang, PhD, Jianguang Chen, PhD, Yongchao Wang, MS, Aditya Mandawat, BS, Pearl Lee, BS, Peter Atadja, PhD, Kapil Bhalla, MD

Blood (2007) 110 (11): 807.

https://doi.org/10.1182/blood.V110.11.807.807

Published: 2007

Journal Articles

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis Giles, Norbert Gattermann, Kapil Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O'Brien, Mark Litzow, Ravi Bhatia, Francisco Cervantes, Ariful Haque, Yaping Shou, Debra J. Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre

Blood (2007) 110 (10): 3540–3546.

https://doi.org/10.1182/blood-2007-03-080689

Published: 2007

Includes: Supplemental data

Journal Articles

Inhibition of Histone Deacetylase (HDAC) 6 and/or Heat Shock Protein (HSP) 90: A Strategy To Abrogate Multi-Level Protective Responses to Misfolded Proteins Induced by Proteasome Inhibitors in Human Leukemia Cells.

Rekha Rao, PhD, Warren Fiskus, PhD, Bryan Herger, PhD, Peter Atadja, PhD, Kapil Bhalla, MD

Blood (2006) 108 (11): 257.

https://doi.org/10.1182/blood.V108.11.257.257

Published: 2006

Journal Articles

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Jeffrey Lancet, MD, Maria R. Baer, MD, Ivana Gojo, MD, M. Burton, M. Quinn, S.M. Tighe, Kapil Bhalla, MD, K. Kersey, S. Wells, Z. Zhong, PhD, B. Sadler, Maher Albitar, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS

Blood (2006) 108 (11): 1961.

https://doi.org/10.1182/blood.V108.11.1961.1961

Published: 2006

Journal Articles

Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML.

Bryan Herger, PhD, Warren Fiskus, Ph.D., Rekha Rao, Ph.D., Kapil Bhalla, M.D.

Blood (2006) 108 (11): 1905.

https://doi.org/10.1182/blood.V108.11.1905.1905

Published: 2006

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant and -Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP).

Philipp le Coutre, MD, Kapil Bhalla, MD, Francis Giles, MD, Michele Baccarani, MD, Gert J. Ossenkoppele, MD, Andreas Hochhaus, MD, Norbert Gattermann, MD, Teresa Rafferty, MD, Ariful Haque, MD, Aaron Weitzman, MD, Hagop Kantarjian, MD

Blood (2006) 108 (11): 165.

https://doi.org/10.1182/blood.V108.11.165.165

Published: 2006

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

Francis Giles, MD, Philipp le Coutre, MD, Kapil Bhalla, MD, Gianantonio Rosti, MD, G.J. Ossenkopplele, MD, Giuliana Alimena, MD, Aaron Weitzman, MD, Teresa Rafferty, Ming Zheng, MD, Hagop Kantarjian, MD

Blood (2006) 108 (11): 2170.

https://doi.org/10.1182/blood.V108.11.2170.2170

Published: 2006

NARROW

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL.

Targeting Histone Deacetylases and Unfolded Protein Mediated Endoplasmic Reticulum (ER) Stress as a Strategy Against Human Mantle Cell Lymphoma.

Molecular Characterization and Drug-Sensitivity of Pan Histone Deacetylase Inhibitor Resistant Human Acute Myeloid Leukemia Cells.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Inhibition of Histone Deacetylase (HDAC) 6 and/or Heat Shock Protein (HSP) 90: A Strategy To Abrogate Multi-Level Protective Responses to Misfolded Proteins Induced by Proteasome Inhibitors in Human Leukemia Cells.

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML.

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant and -Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP).

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only